Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) – Pipeline Review, H1 2018

Global Markets Direct’s, ‘Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) – Pipeline Review, H1 2018’, provides in depth analysis on Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology, Hematological Disorders, Central Nervous System, Other Diseases, Immunology, Infectious Disease and Metabolic Disorders under development targeting Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

– The report provides a snapshot of the global therapeutic landscape for Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.)

– The report reviews Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) targeted therapeutics and enlists all their major and minor projects

– The report assesses Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

4SC AG

Beactica AB

Celgene Corp

GlaxoSmithKline Plc

Imago BioSciences Inc

Incyte Corp

Mirati Therapeutics Inc

Oryzon Genomics SA

Takeda Pharmaceutical Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC

1.) Overview

Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC

1.) Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC

1.) Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC

1.) Companies Involved in Therapeutics Development

4SC AG

Beactica AB

Celgene Corp

GlaxoSmithKline Plc

Imago BioSciences Inc

Incyte Corp

Mirati Therapeutics Inc

Oryzon Genomics SA

Takeda Pharmaceutical Co Ltd

Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC

1.) Drug Profiles

4SC-202 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CC-90011 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs to Inhibit KDM1A and PRKCQ for Metastatic Breast Cancer Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSK-2879552 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IMG-7289 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INCB-59872 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ORY-2001 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ORY-3001 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RASP-201 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RN-1 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit KDM1A for Acute Myelocytic Leukemia Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit KDM1A for Leukemias Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit KDM1A, HDAC1 and HDAC2 for Melanoma Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit LSD1 for Small Cell Lung Cancer and Acute Myelocytic Leukemia Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Oncology Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit KDM1A for Acute Myeloid Leukemia Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit KDM1A for Gastric Cancer Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit LSD-1 for Oncology Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit LSD1 for Alzheimer's Disease, Oncology and Viral Infections Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit LSD1 for Glioblastoma Multiforme Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit LSD1 for Obesity, Type 2 Diabetes and Prostate Cancer Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SP-2509 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SP-2577 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Inhibit KDM1A for Oncology Drug Profile

Product Description

Mechanism Of Action

R&D Progress

T-3775440 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAK-418 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC

1.) Dormant Products

Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC

1.) Discontinued Products

Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC

1.) Product Development Milestones

Featured News & Press Releases

Apr 04, 2018: ORYZON receives approval to start ETHERAL: a Phase IIa clinical trial in Alzheimer’s Disease with ORY-2001

Feb 21, 2018: Oryzon to present at upcoming international conferences

Feb 01, 2018: Imago BioSciences Receives FDA Approval of IND Application for the Treatment of Myeloid Malignancies

Jan 29, 2018: ORYZON announces First Patient In in ORY-2001 MS Phase IIA trial SATEEN and presents new data on ORY-2001 at the third annual ACTRIMS Forum 2018 in San Diego

Jan 23, 2018: ORYZON to present at two US investor conferences

Jan 04, 2018: ORYZON to Present at the Neuroscience Innovation Forum in San Francisco

Dec 04, 2017: Preclinical Efficacy Data on Sickle Cell Disease of ORY-3001, a LSD1 inhibitor from ORYZON, to be presented at ASH 2017

Nov 13, 2017: ORYZON to present new preclinical data of ORY-2001 at the Neuroscience 2017 meeting organized by the Society for Neuroscience

Oct 31, 2017: ORYZON receives approval from AEMPS to start SATEEN: a Phase IIA clinical trial in Multiple Sclerosis with ORY-2001

Oct 09, 2017: ORYZON to present new data on its anti-neurodegenerative drug ORY-2001 at the International Conference on Multiple Sclerosis ECTRIMS-ACTRIMS

Sep 19, 2017: Imago BioSciences Doses First Patients in Phase 1/2 Study of IMG-7289 in Myelofibrosis

Jul 24, 2017: ORYZON presents final data on the Phase I trial with ORY-2001 at the Alzheimers Association International Conference (AAIC-2017)

Jul 19, 2017: Imago BioSciences Doses First Patients in the Phase 2a Portion of the Study of IMG-7289 in Acute Myeloid Leukemia and Myelodysplastic Syndrome

Jun 11, 2017: First patient enrolled in Phase Ib/II study SENSITIZE of 4SC-202 in melanoma

Apr 24, 2017: ORYZON Announces New Grant from Alzheimer's Drug Discovery Foundation (ADDF) to develop a companion marker for its ORY-2001 epigenetic drug

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indications, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Number of Products under Investigation by Universities/Institutes, H1 2018

Products under Investigation by Universities/Institutes, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by 4SC AG, H1 2018

Pipeline by Beactica AB, H1 2018

Pipeline by Celgene Corp, H1 2018

Pipeline by GlaxoSmithKline Plc, H1 2018

Pipeline by Imago BioSciences Inc, H1 2018

Pipeline by Incyte Corp, H1 2018

Pipeline by Mirati Therapeutics Inc, H1 2018

Pipeline by Oryzon Genomics SA, H1 2018

Pipeline by Takeda Pharmaceutical Co Ltd, H1 2018

Dormant Products, H1 2018

Dormant Products, H1 2018 (Contd..1), H1 2018

Discontinued Products, H1 2018

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports